New hope to tame risky heart drugs
NCT ID NCT06062966
Summary
This early-stage study is testing whether a drug that blocks inflammation (anakinra) can make patients with very advanced heart failure more sensitive to their current heart-stimulating medications (inotropes). The goal is to see if patients can use lower, safer doses of these risky drugs while still getting symptom relief. The study will enroll about 20 patients who are already on a stable dose of inotropes to measure changes in inflammation and required medication dose.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEART FAILURE are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Virginia Commonwealth University
RECRUITINGRichmond, Virginia, 23284, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.